Related Experiment Video
Updated: May 28, 2025
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Clinical Burden and Healthcare Resource Use of Asthma in Children in the UK
Imène Gouia1, Florence Joulain1, Yi Zhang2
1HEVA (Health Economics and Value Assessment), Sanofi, Gentilly, France.
Insights
Pediatric asthma in the UK leads to more severe exacerbations and higher healthcare costs as severity increases. This study quantifies the clinical and economic burden of childhood asthma in the UK.
Area of Science:
- Pediatric Pulmonology
- Health Economics
- Epidemiology
Background:
- UK pediatric asthma prevalence is among Europe's highest.
- Childhood asthma data is lacking compared to adult data.
- Assessed clinical and economic burden of pediatric asthma in the UK.
Purpose of the Study:
- To assess the clinical and economic burden of asthma in UK children.
- To understand the impact of pediatric asthma.
- To stratify burden by asthma severity.
Main Methods:
- Retrospective, case-matched, longitudinal analysis (2017).
- Used Clinical Practice Research Datalink GOLD, Hospital Episode Statistics, and Office for National Statistics data.
- Included children aged 6-11 years, comparing asthma patients to matched non-asthma controls.
Main Results:
- Severe exacerbation rates per patient-year (PPY) increased with severity (0.06 mild, 0.17 moderate, 0.31 severe).
- Moderate and severe asthma significantly increased exacerbation risk (IRR 2.87 and 5.19, respectively) versus mild asthma.
- Increased healthcare resource utilization (HCRU) and costs associated with higher asthma severity (total-cost ratios: 1.58 mild, 2.56 moderate, 3.42 severe).
Conclusions:
- Increasing pediatric asthma severity in the UK correlates with higher risks of severe exacerbations and re-exacerbations.
- Greater asthma severity is linked to increased healthcare resource utilization and associated costs.
- The findings highlight the significant clinical and economic impact of pediatric asthma in the UK.
Background:
UK pediatric asthma prevalence is among the highest in Europe, and although the clinical and economic burden of asthma in UK adults is well described, childhood asthma data is lacking. We assessed the clinical and economic burden of asthma in children in the UK to better understand the impact of pediatric asthma.
Methods:
This was a retrospective, case-matched, longitudinal analysis using the Clinical Practice Research Datalink GOLD database and linked patient-level data (Hospital Episode Statistics and Office for National Statistics datasets) of selected patient (aged 6-11 years) records in 2017. Severe exacerbation and re-exacerbation rates per patient-year (PPY), all-cause healthcare resource utilization (HCRU), and HCRU-related costs were assessed in asthma patients versus matched non-asthma controls, stratified by severity.
Results:
Among 5950 patients, severe exacerbation rate was 0.06, 0.17 and 0.31 PPY for mild, moderate, and severe asthma, respectively. Incident rate of severe exacerbations were higher for moderate asthma (incident rate ratios [IRR; 95% CI] 2.87 [2.30-3.56], P<0.0001) and severe asthma (5.19 [4.20-6.41], P<0.0001) versus mild asthma. Risk of re-exacerbation was significantly increased for severe versus mild asthma (hazard ratio [95% CI]: 2.98 [1.90-4.65], P<0.001). All-cause HCRU (IRR [95% CI]) was higher in severe asthma patients versus controls (primary care: 3.81 [3.54-4.09], P<0.0001; inpatient admissions: 3.23 [2.31-4.62], P<0.0001]); total-cost ratios relative to controls for mild, moderate, and severe asthma were 1.58 (1.39-1.78, P<0.0001), 2.56 (1.97-3.33, P<0.0001), and 3.42 (2.54-4.61, P<0.0001), respectively. Asthma-related costs increased with severity (total-cost ratios: moderate versus mild, 1.68 [1.45-1.97], P<0.0001; severe versus mild, 2.67 [2.21-3.25], P<0.0001).
Conclusion:
In children with asthma in the UK, increasing disease severity was associated with increased risk of severe exacerbations, re-exacerbations, and increased HCRU and costs.
Related Concept Videos
01:24Asthma-III: Symptoms and Complications
Classification of Asthma
01:29Asthma-I: Introduction
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:26Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:30Asthma-IV: Nursing Management
First, in...